Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
six
months ended in Dec. 2025,
Aspen Pharmacare Holdings paid$0 Mil more to buy back shares than it received from issuing new shares.
It spent$21 Mil paying down its debt.
It paid$0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It spent$56 Mil paying cash dividends to shareholders.
It received$0 Mil on other financial activities.
In all, Aspen Pharmacare Holdingsspent$77 Mil on financial activities for the
six
months ended in Dec. 2025.
Aspen Pharmacare Holdings (OTCPK:APNHY) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Aspen Pharmacare Holdings's issuance of stock for the
six
months ended in Dec. 2025 was $0 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Aspen Pharmacare Holdings's repurchase of stock for the
six
months ended in Dec. 2025 was $0 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Aspen Pharmacare Holdings's net issuance of debt for the
six
months ended in Dec. 2025 was $-21 Mil.
Aspen Pharmacare Holdings spent$21 Mil paying down its debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Aspen Pharmacare Holdings's net issuance of preferred for the
six
months ended in Dec. 2025 was $0 Mil.
Aspen Pharmacare Holdings paid$0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Aspen Pharmacare Holdings's cash flow for dividends for the
six
months ended in Dec. 2025 was $-56 Mil.
Aspen Pharmacare Holdings spent$56 Mil paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Aspen Pharmacare Holdings's other financing for the
six
months ended in Dec. 2025 was $0 Mil.
Aspen Pharmacare Holdings received$0 Mil on other financial activities.
Aspen Pharmacare Holdings Cash Flow from Financing Related Terms
Aspen Pharmacare Holdings Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for Aspen Pharmacare Holdings's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aspen Pharmacare Holdings Cash Flow from Financing Chart
Aspen Pharmacare Holdings Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Aspen Pharmacare Holdings's Cash from Financing for the fiscal year that ended in Jun. 2025 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-145 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of $-145 Mil mean?
Aspen Pharmacare Holdings (APNHY) has a Cash Flow from Financing of $-145 Mil as of Dec. 2025. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Aspen Pharmacare Holdings and its competitors.
Is Aspen Pharmacare Holdings' Cash Flow from Financing too high?
Aspen Pharmacare Holdings' current Cash Flow from Financing is $-145 Mil. Overall, Aspen Pharmacare Holdings has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aspen Pharmacare Holdings' Cash Flow from Financing compare to ZTS and UTHR?
Aspen Pharmacare Holdings' Cash Flow from Financing of $-145 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Drug Manufacturers company?
A good Cash Flow from Financing depends on the Drug Manufacturers industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Aspen Pharmacare Holdings and its competitors. Aspen Pharmacare Holdings's current Cash Flow from Financing is $-145 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspen Pharmacare Holdings stock overvalued right now?
Based on GuruFocus' analysis, Aspen Pharmacare Holdings (APNHY) is currently considered Modestly Undervalued. The stock's GF Value™ is $10.03, compared to a current price of $8.89 — trading 11.4% below its estimated fair value. The current Cash Flow from Financing is $-145 Mil. Aspen Pharmacare Holdings' overall GF Score™ is 73/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Aspen Pharmacare Holdings (APNHY), the current Cash Flow from Financing is $-145 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aspen Pharmacare Holdings (APNHY) Overvalued in 2026?
Based on GuruFocus' analysis, Aspen Pharmacare Holdings stock appears to be undervalued.
The current stock price of $8.89 is trading 11.4% below its estimated GF Value™ of $10.03.
GuruFocus considers Aspen Pharmacare Holdings to be Modestly Undervalued.
Key valuation signals for APNHY:
Cash Flow from Financing: $-145 Mil
GF Value™: $10.03 vs. price of $8.89 (11.4% below fair value)
No single metric tells the full story. See the APNHY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aspen Pharmacare Holdings Ltd is a multinational pharmaceutical company. The group focuses on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets. The business segments of the group are split between the Commercial Pharmaceuticals and Manufacturing segments. The Commercial Pharmaceuticals business segments are: Injectables, Over-the-counter, and Prescription. The Manufacturing business segments are: Active Pharmaceutical Ingredients, Finished Dose Form, and Heparin. Its geographic regions are Africa Middle East, Europe CIS, Australasia, Asia, and America.
73GF Score
Get the complete analysis for APNHY
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APNHY has been successfully added to your 
